Famciclovir ( DrugBank: Famciclovir )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 11 | Myasthenia gravis | 2 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 2 |
11. Myasthenia gravis
Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100049088 | 2021-08-01 | 2021-07-20 | Evaluation of the effect of famciclovir anti-Epstein-Barr virus therapy on surgical treatment of patients with thymoma complicated with myasthenia gravis | Evaluation of the effect of famciclovir anti-Epstein-Barr virus therapy on surgical treatment of patients with thymoma complicated with myasthenia gravis | thymoma | test group:Famciclovir antiviral treatment during perioperative period;Control group:Routine treatment of perioperative period; | Tianjin Medical University affiliated General Hospital | NULL | Pending | Both | test group:72;Control group:72; | N/A | China | ||
| 2 | ChiCTR2100048785 | 2021-08-01 | 2021-07-16 | Evaluation of the effect of famciclovir anti-Epstein-Barr virus therapy on surgical treatment of patients with myasthenia gravis and thymic hyperplasia | Evaluation of the effect of famciclovir anti-Epstein-Barr virus therapy on surgical treatment of patients with myasthenia gravis and thymic hyperplasia | myasthenia gravis | Experimental group:Famciclovir antiviral treatment during perioperative period;Control group:No; | Tianjin Medical University affiliated General Hospital | NULL | Pending | Both | Experimental group:60;Control group:60; | N/A | China |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05283551 (ClinicalTrials.gov) | November 25, 2020 | 24/2/2022 | Famciclovir in Multiple Sclerosis | A Phase 2 Open Label Clinical Trial to Determine the Effect of Famciclovir on Epstein-Barr Virus Activity as Measured by EBV Shedding in Saliva of Patients With Multiple Sclerosis. | Multiple Sclerosis | Drug: Famciclovir | Queen Mary University of London | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | United Kingdom |
| 2 | EUCTR2019-000169-19-GB (EUCTR) | 03/09/2019 | 05/06/2019 | Clinical trial to determine the effect of Famciclovir on Epstein Barr virus levels in the saliva of patients with Multiple Sclerosis. | Clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in saliva of patients with Multiple Sclerosis. - Famciclovir in Multiple Sclerosis | Epstein Barr virus infection in people with multiple sclerosis. MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: LLT;Classification code 10014077;Term: EBV infection;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02] | Trade Name: Famciclovir Product Name: Famciclovir INN or Proposed INN: Famciclovir Other descriptive name: 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester | Queen Mary University London | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | United Kingdom |